Scientists don’t yet fully understand how GLP-1 drugs like Ozempic affect the brain’s reward pathways, but there are ...

China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin disease met the main goal in a mid-stage study. Here are some details: * The ...

The pharmaceutical corporation Pfizer announced Tuesday that its experimental weight loss jab showed solid results when taken monthly during an ongoing mid-stage clinical trial. And there was no ...

Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the country’s National Medical Products Administration (NMPA) has ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Low PE High Dividend Stocks to Buy Right Now. On March 6, Reuters reported ...

Pfizer forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions. Revenue in 2026 will be $59.5 ...

Sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak with the end of the pandemic. Their sales came down to around $11 billion in 2024 and $6.7 billion in 2025 from ...